875781-41-2

Basic information

• Product Name: 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine
• Synonyms: 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine;5-broMo-3-(2-(triMethylsilyl)ethynyl)pyrazin-2-aMine;Pyrazinamine, 5-bromo-3-[(trimethylsilyl)ethynyl]-;5-bromo-3-[2-(trimethylsilyl)ethynyl]-2-Pyrazinamine;5-Bromo-3-((trimethylsilyl);EOS-61575
• CAS NO: 875781-41-2
• Molecular Formula: C₉H₁₂BrN₃Si
• Molecular Weight: 270.20118
• Mol File: 875781-41-2.mol
• Article Data: 29

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine(875781-41-2)
• EPA Substance Registry System: 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine(875781-41-2)

Safety Data

• Hazardous Substances Data: 875781-41-2(Hazardous Substances Data)

Usage

General Description

5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine is a chemical compound with the molecular formula C9H11BrN4Si. It is a brominated pyrazine derivative that is commonly used in the synthesis of pharmaceuticals and organic compounds. The presence of bromine and trimethylsilyl ethynyl groups in the molecule makes it a valuable building block for the construction of various biologically active compounds. 5-bromo-3-((trimethylsilyl)ethynyl)pyrazin-2-amine is often employed in medicinal chemistry research and drug discovery programs due to its synthetic versatility and potential pharmacological properties. Additionally, the trimethylsilyl group in the molecule provides steric hindrance, which can affect its reactivity and influence its interactions with other chemical compounds.

Upstream product

• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 1066-54-2 trimethylsilylacetylene 

Downstream Products

• 1201186-54-0 2-bromo-5-(p-toluenesulfonyl)-5H-pyrrolo[2,3-b]pyrazine 
• 1232423-55-0 tert-butyl N-(5-bromo-3-ethynyl-pyrazin-2-yl)-N-tert-butoxycarbonyl-carbamate 
• 1349734-86-6 di-tert-butyl (5-bromo-3-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)carbamate 
• 1349734-89-9 di-tert-butyl (5-bromo-3-(3-(4-(bromomethyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)carbamate 
• 1349734-88-8 tert-butyl N-[5-bromo-3-[3-(p-tolyl)isoxazol-5-yl]pyrazin-2-yl]-N-tert-butoxycarbonylcarbamate 
• 1349734-93-5 tert-butyl N-[[4-[5-[3-[bis(tert-butoxycarbonyl)amino]-6-bromopyrazin-2-yl]isoxazol-3-yl]phenyl]methyl]-N-cyclopropylcarbamate 
• 1349734-90-2 di-tert-butyl (5-bromo-3-(3-(4-((isopropylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-yl)carbamate 
• 1349734-98-0 1-((4-(5-(3-amino-6-bromopyrazin-2-yl)isoxazol-3-yl)benzyl)amino)-2-methylpropan-2-ol 
• 1349734-97-9 5-bromo-3-(3-(4-(chloromethyl)phenyl)isoxazol-5-yl)pyrazin-2-amine 
• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 875781-44-5 2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine 
• 875781-45-6 2-bromo-7-iodo-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229583-75-8 2-bromo-7-(1H-indol-5-yl)-5-tosyl-5H-pyrrolo[3,2-b]pyrazine 
• 1229582-37-9 7-(1H-indol-5-yl)-2-(3,4,5-trimethoxyphenyl)-5H-pyrrolo[3,2-b]pyrazine 

Relevant articles and documents

Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib

Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.

Discovery and Toxicological Profiling of Aminopyridines as Orally Bioavailable Selective Inhibitors of PI3-Kinase γ

Using a novel physiologically relevant in vitro human whole blood neutrophil shape change assay, an aminopyrazine series of selective PI3Kγinhibitors was identified and prioritized for further optimization. Severe solubility limitations associated with the series leading to low oral bioavailability and poor exposures, especially at higher doses, were overcome by moving to an aminopyridine core. Compound 33, with the optimal balance of on-target activity, selectivity, and pharmacokinetic parameters, progressed into in vivo studies and demonstrated good efficacy (10 mg/kg) in a rat model of airway inflammation. Sufficient exposures were achieved at high doses to support toxicological studies, where unexpected inflammatory cell infiltrates in cardiovascular tissue prevented further compound development.

Influenza virus replication inhibitors and uses thereof (by machine translation)

The invention provides a compound as an influenza virus replication inhibitor, a method for preparing the same, a pharmaceutical composition containing the compound and application. (by machine translation)